For example, the recently approved moxetumomab pasudotox combine the PE38 Pseudomonas endotoxin with and anti-CD22 scFv, and it is suitable for the treatment of hairy cell leukemia [27]. This evidence concerns the gene CD22 and hairy cell leukemia.